Gilteritinib (Xospata®) accepted for use within NHS Scotland
Gilteritinib oral tablet is approved as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia with a FLT3 mutation.
Source:
Scottish Medicines Consortium